Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
Cédric Peleman(University of Antwerp), Tom Vanden Berghe(VIB-UGent Center for Medical Biotechnology), Isabel Pintelon(University of Antwerp), Koen Augustyns(University of Antwerp), Emily Van San(University of Antwerp), Wilhelmus J. Kwanten(Antwerp University Hospital), Annelies Van Eyck(University of Antwerp), Benedicte Y. De Winter(University of Antwerp), Behrouz Hassannia(Albert Einstein College of Medicine), Hao Zheng(Nagoya University), Winnok H. De Vos(University of Antwerp), Joris De Man(University of Antwerp), Wout Arras(University of Antwerp), An Verrijken(University of Antwerp), Shinya Toyokuni(University of Sydney), Sven Francque(University of Antwerp), Ann Driessen(University of Antwerp), Annemieke Smet(University of Antwerp), Christophe Van Steenkiste(University of Antwerp), Mikhaïl A. Van Herck(University of Antwerp), Luisa Vonghia(University of Antwerp), Baptiste Oosterlinck(University of Antwerp), Lieve Vits(University of Antwerp), Ine Koeken(University of Antwerp), Geraldine Veeckmans(University of Antwerp), Magali Walravens(University of Antwerp), Nateneal Beyene(University of Antwerp), Edissa Kayirangwa(University of Antwerp), Luc Van Nassauw(University of Antwerp), Stig Hellemans(University of Antwerp), Eveline Dirinck(University of Antwerp)
Cited by 36
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Persistent oxidative stress in cancer
|FEBS Letters|1995|1.2k